Delivery Order SPE2DB20D9127-SPE2DB21FD3SQ
- Not listed
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The current...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC) valued at up to $499,999,999. The contract runs through December 31, 2025 and allows the DLA to issue firm fixed-price delivery orders to DMS Pharmaceutical Group for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC) valued at up to $499,999,999. The contract covers a wide range of pharmaceutical products, including common medications as well as specialized drugs and medical supplies, to fulfill the recurring medical supply needs of Department of Defense (DoD) healthcare facilities worldwide. The...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers the provision of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers the provision of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC) valued at up to $499,999,999. The contract is for the supply of various pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military health facilities worldwide. The...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $11,849.81 under a larger indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) valued at up to $499,999,999. The IDC, which runs through December 31, 2025, allows the DLA to issue firm fixed-price delivery orders to DMS Pharmaceutical Group for a comprehensive range of pharmaceutical items, including both common and...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) valued at $499,999,999 and valid through November 2026. The delivery order, valued at $89,953.38, is for the provision of a range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) as a delivery order under the SPE2DB indefinite delivery contract valued up to $499,999,999. The contract is for the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military health...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract, which does not have a set-aside designation, is for the delivery of a variety of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB21FD3SQDelivery Order
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program, an Indefinite Delivery Contract (IDC) valued at $499,999,999 and valid through November 2026. The contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The specific award for $16,168.05 is for the delivery of Somatuline Depot 90 mg/0.3 ml medication. This contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its small business status to secure direct federal awards across multiple product categories and medical domains. As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has consistently demonstrated its capability to provide a diverse array of pharmaceutical products to the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/3/21 |